Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Cannabis-based medications prove effective in relieving pain

Cannabis-based medications have been proved to relieve pain. This is the conclusion drawn by Franjo Grotenhermen and Kirsten Müller-Vahl in issue 29-30 of Deutsches Ärzteblatt International.

7 Aug 2012

Changes in monocytes are biomarker for amyotrophic lateral sclerosis

Researchers from Brigham and Women's Hospital (BWH) are the first to discover that changes in monocytes (a type of white blood cell) are a biomarker for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. This finding also brings the medical community a step closer toward a new treatment for the debilitating neurological disease that affects approximately 30,000 Americans.

7 Aug 2012

Fainting appears to have strong genetic predisposition

Fainting has a strong genetic predisposition, according to new research published in the August 7, 2012, print issue of Neurology, the medical journal of the American Academy of Neurology. Fainting, also called vasovagal syncope, is a brief loss of consciousness when your body reacts to certain triggers, such as emotional distress or the sight of blood.

7 Aug 2012

Weill Cornell Medical College receives NCATS grant to fund Clinical and Translational Science Center

Weill Cornell Medical College has received $49.6 million from the National Center for Advancing Translational Sciences (NCATS), of the National Institutes of Health (NIH), to fund its Clinical and Translational Science Center (CTSC).

3 Aug 2012

Caffeine may ease movement symptoms of Parkinson's

While drinking caffeine each day does not appear to help improve sleepiness among people with Parkinson's disease, it may have a benefit in controlling movement, according to new research published in the August 1, 2012, online issue of Neurology, the medical journal of the American Academy of Neurology.

3 Aug 2012

B-cell substances may play a role in MS progression

Wayne State University School of Medicine researchers, working with colleagues in Canada, have found that one or more substances produced by a type of immune cell in people with multiple sclerosis (MS) may play a role in the disease's progression. The finding could lead to new targeted therapies for MS treatment.

2 Aug 2012

Advanced understanding of neurodegenerative diseases achieved by Trophos

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announces today the conclusion of the pan-European MitoTarget Project, the EU funded orphan disease project, with submission of the final report to the EC.

31 Jul 2012

Long-term interferon beta benefits unclear in MS

A large “real-world” study fails to show reduced disability progression in patients with relapsing-remitting multiple sclerosis given interferon beta.

26 Jul 2012

Elan second quarter total revenue increases 6% to $288.0 million

Elan Corporation, plc today reported its second quarter and first half 2012 financial results.

25 Jul 2012

Questcor second quarter net sales increase to $112.5 million

Questcor Pharmaceuticals, Inc. today reported financial results for the second quarter and six months ended June 30, 2012.

24 Jul 2012

Watching YouTube videos may help treat benign paroxysmal positional vertigo

Watching videos on YouTube may be a new way to show the treatment for a common cause of vertigo, which often goes untreated by physicians, according to a study published in the July 24, 2012, print issue of Neurology, the medical journal of the American Academy of Neurology.

24 Jul 2012

PAMAM G-3 actually prevents activation of the process that leads to thrombosis

A compound that mops up debris of damaged cells from the bloodstream may be the first in a new class of drugs designed to address one of medicine's most difficult challenges -- stopping the formation of blood clots without triggering equally threatening bleeding.

24 Jul 2012

XenoPort initiates XP23829 Phase 1 study in healthy adults

XenoPort, Inc. announced today that the first subjects have been dosed in a Phase 1, randomized, double-blind, two-period crossover, food effect comparison study of XP23829 in healthy adults. The trial is designed to assess the pharmacokinetics, safety and tolerability of a single dose of XP23829 administered in both fasted and fed conditions.

24 Jul 2012

Short-term infection with intestinal worms may provide long-term protection against TID

Short-term infection with intestinal worms may provide long-term protection against type I diabetes (TID), suggests a study conducted by William Gause, PhD, and colleagues at the University of Medicine and Dentistry of New Jersey-New Jersey Medical School.

20 Jul 2012

Teva contributes $2.5M to The Franklin Institute for development of neuroscience exhibit

The Franklin Institute has received a $2.5 million contribution from leading global pharmaceutical company Teva Pharmaceuticals to develop a signature innovative exhibit at the museum exploring neuroscience and the human brain, entitled Your Brain. This contribution brings The Franklin Institute's Inspire Science fundraising campaign total to $65 million.

20 Jul 2012

New AAN guideline recommends several treatments for people with Huntington's chorea

A new guideline released by the American Academy of Neurology recommends several treatments for people with Huntington's disease who experience chorea—jerky, random, uncontrollable movements that can make everyday activities challenging.

19 Jul 2012

High ceramide levels may increase a person's risk of AD

Higher levels of a certain fat in the blood called ceramides may increase a person's risk of developing Alzheimer's disease, according to a study published in the July 18, 2012, online issue of Neurology, the medical journal of the American Academy of Neurology.

19 Jul 2012

Interferon beta not associated with less progression of disability in patients with RRMS

Among patients with relapsing-remitting multiple sclerosis (MS), treatment with the widely-prescribed drug to treat MS, interferon beta, was not associated with less progression of disability, according to a study in the July 18 issue of JAMA.

18 Jul 2012

Mobile Music Touch may improve motor skills, sensation for people with paralyzing SCI

Georgia Tech researchers have created a wireless, musical glove that may improve sensation and motor skills for people with paralyzing spinal cord injury (SCI).

18 Jul 2012

Premier research institutions, Biogen Idec partner to sequence genomes of patients with ALS

Biogen Idec today announced that it has entered into a research collaboration with premier academic and research institutions to sequence the genomes of up to 1,000 patients with amyotrophic lateral sclerosis (ALS) in an effort to gain a deeper understanding about the fundamental genetic causes of ALS.

17 Jul 2012